The Cre/loxP system has been used extensively for conditional mutagenesis in mice.
Reporters of Cre activity are important for defining the spatial and temporal extent of Cre‐mediated …

Activating mutations in the proto-oncogene KRAS are a hallmark of pancreatic ductal
adenocarcinoma (PDAC), an aggressive malignancy with few effective therapeutic options. Despite …

Small cell lung cancer (SCLC) is an aggressive lung cancer subtype with extremely poor
prognosis. No targetable genetic driver events have been identified, and the treatment …

Obesity is a major modifiable risk factor for pancreatic ductal adenocarcinoma (PDAC), yet
how and when obesity contributes to PDAC progression is not well understood. Leveraging …

The initiation and progression of many human cancers involve either somatic activation of
protooncogenes or inactivation of tumor-suppressor genes (TSGs) in sporadic cells. Although …

Although it has become increasingly clear that cancers display extensive cellular
heterogeneity, the spatial growth dynamics of genetically distinct clones within developing solid …

Activating mutations in KRAS are the hallmark genetic alterations in pancreatic ductal
adenocarcinoma (PDAC) and the key drivers of its initiation and progression. Longstanding efforts …

Human pancreatic ductal adenocarcinoma (PDAC) contains a distinctively dense stroma
that limits the accessibility of anticancer drugs, contributing to its poor overall prognosis. …

Alterations in three-dimensional (3D) genome structures are associated with cancer 1–5.
However, how genome folding evolves and diversifies during subclonal cancer progression in …

The transcription factor p53 is a tumor suppressor capable of inducing cell cycle arrest,
senescence, and apoptosis. Both truncating loss-of-function mutations and point mutations of the …